Cefaly Technology, the creators of the first FDA-approved transcutaneous electrical nerve stimulation device specifically authorised for use prior to the onset of migraine pain, is set to announce significant breakthroughs in migraine treatment at the EUROHEADPAIN Midterm Meeting at the International Headache Society Congress in Valencia, Spain, from 14–17 May, 2015.
On 14 May at a meeting of EUROHEADPAIN, a major European research project focused on migraines, Cefaly Technology will present three significant patent pending systems of neuromodulation that are in development. These systems would help to alter nerve activity in migraine patients by combining different currents targeted at specific cranial zones. “Thanks to these new systems, over the next few years, we will be able to develop the most efficient and safest treatments for migraines,” said Pierre Rigaux, chief executive officer of Cefaly Technology.
On 16 May, during the Late-Breaking Oral presentations, results will be released from a clinical trial on cerebral changes as demonstrated by positron emission tomography (PET) scan in migraine patients treated with a Cefaly device. The PET scan used a radioactive substance called a tracer to show how the brain and its tissues are working under the influence of a Cefaly.
“New data shows the Cefaly action on brain metabolism in specific cortical zones of migraine patients,” said Rigaux. “The modifications observed through brain imaging reinforce the strong clinical data on safety and efficacy that led to the FDA approval.”
In March 2014, the FDA approved the prescription-only, headband-like, device that uses tiny electrical impulses to stimulate the trigeminal nerve to reduce the frequency and intensity of migraines. At that time, it reached its decision using data from a randomised double blinded clinical trial implemented in five university clinics in Belgium; as well as a patient satisfaction study of 2,313 Cefaly users in France.
